KDR and nonpapillary renal cell carcinoma: The current first-line standard of care for good risk metastatic clear-cell RCC (ccRCC) is the tyrosine kinase inhibitors (TKIs) targeting vascular endothelial growth factor receptor (VEGFR) [6].